A detailed history of Trexquant Investment LP transactions in Evolus, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 247,560 shares of EOLS stock, worth $2.9 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
247,560
Previous 142,403 73.84%
Holding current value
$2.9 Million
Previous $1.55 Million 159.55%
% of portfolio
0.05%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$10.66 - $17.48 $1.12 Million - $1.84 Million
105,157 Added 73.84%
247,560 $4.01 Million
Q2 2024

Aug 13, 2024

SELL
$10.45 - $13.76 $1.06 Million - $1.4 Million
-101,626 Reduced 41.65%
142,403 $1.55 Million
Q1 2024

May 14, 2024

BUY
$9.99 - $14.91 $858,680 - $1.28 Million
85,954 Added 54.38%
244,029 $3.42 Million
Q4 2023

Feb 09, 2024

BUY
$7.6 - $10.53 $514,352 - $712,649
67,678 Added 74.87%
158,075 $1.66 Million
Q3 2023

Nov 13, 2023

SELL
$7.15 - $10.2 $66,630 - $95,053
-9,319 Reduced 9.35%
90,397 $826,000
Q2 2023

Aug 11, 2023

SELL
$7.23 - $10.52 $97,272 - $141,536
-13,454 Reduced 11.89%
99,716 $724,000
Q1 2023

May 15, 2023

BUY
$7.81 - $11.05 $883,857 - $1.25 Million
113,170 New
113,170 $957,000
Q3 2022

Nov 14, 2022

BUY
$7.76 - $13.72 $280,167 - $495,346
36,104 New
36,104 $291,000
Q2 2022

Aug 11, 2022

SELL
$10.22 - $13.94 $137,847 - $188,022
-13,488 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$5.22 - $11.78 $93,218 - $210,367
-17,858 Reduced 56.97%
13,488 $151,000
Q4 2021

Feb 14, 2022

SELL
$5.37 - $8.38 $247,197 - $385,756
-46,033 Reduced 59.49%
31,346 $204,000
Q3 2021

Nov 12, 2021

BUY
$7.36 - $13.67 $569,509 - $1.06 Million
77,379 New
77,379 $590,000

Others Institutions Holding EOLS

About Evolus, Inc.


  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $658M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.